Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.43 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.43 |
| ▸ | CTSA | P10619 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | PTAFR | P25105 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16495723 | 0.81 | MAPT (0.45) | CXCR3CTSASMN1; SMN2GABRA5PTAFR | |
| SCHEMBL1543442 | 0.75 | HPGDS (0.48) | — | |
| SCHEMBL16495565 | 0.74 | PSMD14 (0.55) | — | |
| SCHEMBL16496396 | 0.74 | HCRTR1 (0.58) | LMNASMN1; SMN2 | |
| SCHEMBL16495381 | 0.74 | DRD2 (0.52) | LMNASMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL16496253 | 0.74 | CTSA (0.44) | CTSAGABRA5 | |
| SCHEMBL16496071 | 0.73 | LMNA (0.50) | LMNASMN1; SMN2 | |
| SCHEMBL16496244 | 0.73 | MAPT (0.57) | LMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL1578594 | 0.73 | GAA (0.53) | LMNASMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL16495642 | 0.72 | GAA (0.48) | NPC1RAB9AGABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110306597-A1 | Nicotinamide Derivatives | CRAWFORTH JAMES MICHAEL (GB) | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306597-A1 | Nicotinamide Derivatives | NNT, NAMPT, NQO1 | NOD1 61/4885CXCR3 793/4885CTSA 1235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.